Ad
ACET - Adicet Bio Stock Trading
About | Adicet Bio Inc. (NASDAQ:ACET)
Not available
Quote | Adicet Bio Inc. (NASDAQ:ACET)
| Last: | $1.48 |
|---|---|
| Change Percent: | 2.78% |
| Open: | $1.45 |
| Close: | $1.44 |
| High: | $1.4989 |
| Low: | $1.43 |
| Volume: | 15,798 |
| Last Trade Date Time: | 09/28/2023 03:00:00 am |
News | Adicet Bio Inc. (NASDAQ:ACET)
-
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38 th A...
-
2023-09-01 20:00:14 ET Summary CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. B...
Message Board Posts | Adicet Bio Inc. (NASDAQ:ACET)
| Subject | By | Source | When |
|---|---|---|---|
| AviseAnalytics: 7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST! $ACET Adicet Bio (NASDAQ: ACET) i | AviseAnalytics | investorshangout | 01/24/2022 12:25:33 PM |
| No sell off...guess I bet wrong | masterofdisaster | investorshub | 12/08/2021 7:41:01 PM |
| Phase 1's usually suck wind, I lost $80K | TheFinalCD | investorshub | 12/08/2021 2:58:31 PM |
| It was weird....I think the MMs drop this | masterofdisaster | investorshub | 12/08/2021 12:07:16 PM |
| whats weird is the rally after the offering | TheFinalCD | investorshub | 12/08/2021 4:10:48 AM |
Ad
-
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38 th A...
-
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational ...
-
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43 rd Ann...